Healthcare -
Biotechnology - NASDAQ - US
$ 17.38
1.16 %
$ 1.71 B
Market Cap
-108.62
P/E
1. INTRINSIC VALUE
Balance Sheet
ARS Pharmaceuticals, Inc.
| Current Assets | 334 M |
| Cash & Short-Term Investments | 314 M |
| Receivables | 9.16 M |
| Other Current Assets | 11.1 M |
| Non-Current Assets | 16.9 M |
| Long-Term Investments | 0 |
| PP&E | 1.07 M |
| Other Non-Current Assets | 15.8 M |
| Current Liabilities | 23.4 M |
| Accounts Payable | 9.87 M |
| Short-Term Debt | 42 K |
| Other Current Liabilities | 13.5 M |
| Non-Current Liabilities | 70.9 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 70.9 M |
EFFICIENCY
Earnings Waterfall
ARS Pharmaceuticals, Inc.
| Revenue | 89.1 M |
| Cost Of Revenue | 977 K |
| Gross Profit | 88.2 M |
| Operating Expenses | 91.3 M |
| Operating Income | -3.08 M |
| Other Expenses | -11.1 M |
| Net Income | 8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ARS Pharmaceuticals, Inc.
| Net Income | 8 M |
| Depreciation & Amortization | -7.18 M |
| Capital Expenditures | -563 K |
| Stock-Based Compensation | 14.5 M |
| Change in Working Capital | -1.81 M |
| Others | -5.93 M |
| Free Cash Flow | 13 M |
Wall Street Analysts Price Targets
ARS Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for SPRY of $22 , with forecasts ranging from
a
low of
$14 to a high of $30 .
SPRY Lowest Price Target
Wall Street Target
14 USD
-19.45%
SPRY Average Price Target
Wall Street Target
22 USD
26.58%
SPRY Highest Price Target
Wall Street Target
30 USD
72.61%
4. DIVIDEND
ANALYSIS
SPRY does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ARS Pharmaceuticals, Inc.
Sold
0-3 MONTHS
11.2 M USD 5
3-6 MONTHS
1.93 M USD 2
6-9 MONTHS
32.2 M USD 7
9-12 MONTHS
43.1 M USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m.
globenewswire.com
- 2 days ago
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 1 week ago
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
EUR neffy ( neffy ® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children ( > 30 kg) living with severe allergic reactions
globenewswire.com
- 2 weeks ago
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?
Does ARS Pharmaceuticals, Inc. (SPRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
- 3 weeks ago
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?
The mean of analysts' price targets for ARS Pharmaceuticals, Inc. (SPRY) points to a 78.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
zacks.com
- 3 weeks ago
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'
ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
zacks.com
- 3 weeks ago
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June.
globenewswire.com
- 2 months ago
ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas - CCO Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Josh Schimmer - Cantor Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Andreas Argyrides - Oppenheimer Louise Chen - Scotiabank Operator Good morning and welcome to ARS Pharmaceuticals' Conference Call. At this time, all participants are in listen-only mode.
seekingalpha.com
- 2 months ago
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
zacks.com
- 2 months ago
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m.
globenewswire.com
- 2 months ago
ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as little as $25 (if eligible) in preparation for summer travel and back-to-school SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced neffy ® (epinephrine nasal spray) 1 mg is now available to patients and caregivers by prescription across the U.S. In March 2025, the U.S. Food and Drug Administration approved neffy for the treatment of Type I allergic reactions, including anaphylaxis, in children who are aged four years and older and weigh 15 to < 30 kilograms (33 to < 66 lb.). “Many children fear needles, which can lead parents to delay administering needle-based epinephrine treatments.
globenewswire.com
- 3 months ago
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m.
globenewswire.com
- 3 months ago
8. Profile
Summary
ARS Pharmaceuticals, Inc. SPRY
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.71 B
Dividend Yield
0.00%
Description
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Contact
3525 Del Mar Heights Road, San Diego, CA, 92130
https://ars-pharma.com
IPO
Date
Dec. 4, 2020
Employees
155
Officers
Mr. Eric Karas
Chief Commercial Officer
Ms. Kathleen D. Scott CPA
Chief Financial Officer
Dr. Robert Bell Ph.D.
Co-Founder & Chief Science Officer
Mr. Richard E. Lowenthal M.B.A., M.S., MSMSEL
Co-Founder, President, Chief Executive Officer & Director
Dr. Sarina Tanimoto M.B.A., M.D.
Co-Founder & Chief Medical Officer
Mr. Harris Kaplan M.B.A.
Executive Vice President of Commercial Strategy
Mr. Brian T. Dorsey M.S.
Chief Operating Officer
Mr. Daniel Relovsky
Senior Vice President of Marketing
Mr. Justin Chakma
Chief Business Officer
Mr. Alexander A. Fitzpatrick Esq.
Chief Legal Officer & Secretary